JAIDS Journal of Acquired Immune Deficiency Syndromes
27:509–511 © 2001 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes
Volume 27, 2001

Author Index

Abel S, 96
Aberg J, 153
Abu-Rustum NR, 95
Agins B, 96
Agustí C, 35
Ahdieh L, 432
Ammassari A, 49
Anastos K, 432
Andersen RM, 463
Andía J, 405
Antinori A, 49
Anton KE, 450
APROCO Study Group, 372
Aqeel R, 130
Arpadi SM, 30
Aweeka F, 153

Bacchetti P, 308
Bacellar O, 1
Bailey SL, 71
Balagué M, 229
Balotta C, 499
Bartolomé-Pacheco MJ, 507
Battegay M, 266
Baum MK, 56
Bazin C, 372
Becker S, 210
Beckmann RA, 237
Beijnen JH, 344
Beltzer N, 482
Benito N, 35
Benning L, 432
Bentwich Z, 389
Berlin JA, 281
Bernard-Henry C, 459
Bernasconi A, 209
Bernasconi E, 209
Bertoli A, 499
Besnier J-M, 372
Bijl M, 318
Binson D, 176, 292
Bisset LR, 266
Black FT, 124
Blanch J, 336
Blanchard J, 222
Blanche S, 99
Blanco J-L, 336
Boeri E, 44
Bogner JR, 237
Bond VC, 213
Bonfanti P, 316
Bonjoch A, 229
Borderi M, 315
Borkow G, 389
Bozeman S, 472
Bozzette SA, 463
Braga S, 1
Brambilla AM, 44
Brettle RP, 277
Brown AJL, 277
Brown LK, 135
Browning SW, 105
Buchanan TA, 130
Buchbinder S, 472
Buchbinder SP, 308
Buisson M, 245
Buranapraditkun S, 116
Burgard M, 99

Canchola J, 176
Caramello P, 499
Carnevale G, 499
Carr P, 183
Carrieri MP, 372
Carvalho EM, 1
Castagna A, 44
Catania JA, 176
Cauda R, 321
Ceccaldi J, 161
Celentano DD, 202
Celum C, 472
Chaisson RE, 251
Chaix M-L, 99
Chang J, 176
Chavanet P, 245
Cheever LW, 251
Chêne G, 161, 372
Cheneau C, 459
Cheng-Mayer C, 222
Cherrington JM, 450
Chiphangwi JD, 202
Choi K-H, 176
Cingolani A, 49
Clotet B, 229
Coates T, 176
Cohen CR, 365
Collison EK, 183
Colón HM, 405
Combs CM, 135
Cone RW, 266
Constantine NT, 63
Cooper DA, 116
Cosler L, 20
Costagliola D, 492
Cottalorda J, 99
Cotten-Oldenburg NU, 183
Cozzi-Lepri A, 499
Cramer LA, 417
Cremonini L, 499
Crepaz N, 79
Crombie R, 91
Cruz MA, 405
Cuff PA, 30
Cunningham WE, 463

D'Amico R, 153
d'Arminio-Monforte A, 499
Dabis F, 161
Danés C, 35
De Lazzari E, 336
De Luca A, 49
de Mautort E, 459
De Pablo J, 336
DeBoer JM, 183
Denning P, 467
Deren S, 301, 405
Detels R, 168
Dieleman JP, 318
Diener-West M, 143
Dilley JW, 292
Dolcini MM, 176
Domingo P, 229
Donnell D, 86, 472
Douard D, 99
Doussin A, 99
Dubé MP, 130, 506
Dubs RW, 266
Duong M, 245

Easterbrook PJ, 350
Echevarría S, 507
Edelman DC, 63
Edmondson-Melançon H, 130
Eshetu T, 222

Facchi G, 499
Faggion I, 316
Falkin GP, 301
Farbos S, 161
Filippone WJ, 135

Finlinson HA, 405
Fischer M, 266
Fisher A, 210
Fisher L, 176
Flanigan TP, 135
Fleury H, 99
Flexner C, 153, 210
Forastiere F, 93
Forbici F, 499
Forman VL, 398
Fortuna P, 316
Francia E, 229
Frelinger JA, 417
French Pediatric HIV Infection Study Group, 99
Fuller MD, 450
Furnaz CR, 229
Fusaro RE, 308

Gal J, 153
Gallagher LE, 105
Galvão-Castro B, 1
Garcia-Barrio M, 213
García-Viejo M-A, 336
Gatell JM, 35, 336
Gazzard BG, 350
Gebo KA, 143
Gel S, 229
Gelato MC, 506
George K, 381
Gerber JG, 153, 210
Gettie A, 222
Giorgi J, 168
Gisselquist D, 414
Goebel Frank-D, 237
González J, 35
Goubar A, 492
Grappin M, 245
Greenblatt RM, 432
Grillo R, 49
Grob PJ, 266
Gross M, 86
Gulick R, 153
Guydish JR, 193

Halpern SD, 281
Harouse JM, 222
Hasson H, 44
Haubrich R, 210
Hauck WW, 20
Hays R, 482
HCSUS Consortium, 463
Heiman JR, 176
Hengel RL, 105
Hess-Kempf G, 459
Hessol NA, 308
Hillon P, 245
Hirschel B, 209
HIVNET VPS 001 Protocol Team, 86
Hoetelmans RMW, 344
Hojo K, 91
Holly EA, 272
Holmberg SD, 308
Holodniy M, 260
Hoover DR, 202
Horlick M, 30
Hormel L, 467
Hsu A, 153
Huang M-B, 213
Hughes M, 377
Hughes V, 153
Huo D, 71

Ihler E, 381
Ippolito G, 499
Ives N, 350
Izopet J, 99

Jais J-P, 443
Jensen RH, 272
Jensen-Fangel S, 124
Jin J, 168
Johnson D, 130
Johnston S, 229
Jubault V, 443

Kabugo M, 381
Kahn JG, 482
Kalinkovich A, 389
Kang S-Y, 405
Kashuba ADM, 210
Katz M, 467
Katzenstein DA, 377
Kawasaki K, 91
Kegeles SM, 482
Keiser P, 14
Ketema F, 63
Khan M, 213
Kilmarx PH, 415
Kimari JN, 365
Koblin B, 472
Korattana S, 415
Kotler DP, 30
Krantz V, 459
Kroon EDMB, 116
Kumwenda NI, 202
Kunanusont C, 116
Kuritzkes DR, 7
Kvanli MB, 14

La Placa M, 315
Lai H, 56
Lai S, 56
Laine C, 20
Lally MA, 135
Lamy PD, 450
Lana R, 426
Landonio S, 316
Lang J-M, 459
Lange J, 116, 229, 344
Larsen L, 124
Latkin CA, 398
Laurence J, 91
Lazzarin A, 44
Le Moing V, 372
Lechenadec J, 99
Lee S, 95
Leng Q, 389
Leone G, 321
Leport C, 372
Levesque BG, 135
Lew E, 105
Limpakarnjanarat K, 415
Liomba GN, 202
Liou SH, 377
Lockett SF, 277
López-Escribano H, 507
López-Hoyos M, 507
Lu J, 7
Luber AD, 210
Lucas GM, 251
Lucia MB, 321
Lum PJ, 193
Luna M, 35

Ma F, 56
Machekano RA, 377
Mafigiri D, 381
Mallolas J, 336
Manopaiboon C, 415
Margolick JB, 168
Margot NA, 450
Marimoutou C, 161
Markakis D, 202
Marks G, 79
Marmor M, 472
Martín M, 507
Martín-Carbonero L, 426
Martinelli C, 316
Martínez E, 336
Masquelier B, 99, 372
Massad LS, 95, 432
Mastro TD, 415
Mayaux M-J, 99
McDougal JS, 105
McGrath JW, 381
McKirnan D, 86
McNurlan MA, 506
McQuitty M, 467
Médioni J, 443
Meenhorst PL, 344
Meier AS, 365
Melnick S, 432
Mendoza JL, 426
Mercié P, 161
Metzger D, 86
Metzger DS, 281
Michl G, 237
Middleton D, 277
Mildvan D, 153
Miller MD, 450
Minkoff H, 289, 432
Miotti P, 432
Miró JM, 35
Moatti J-P, 372
Mole L, 260
Monari P, 315

Monno L, 499
Monterroso ER, 71
Moore RD, 143, 251
Moreno A, 35
Morlat P, 161
Moroni M, 499
Moxley M, 432
Moyle G, 350
Muderspach LI, 432
Mugisha E, 381
Mulato AS, 450
Mulder JW, 344
Mullaney BP, 272
Muñoz A, 168
Murri R, 49
Mwachari CW, 365
Mynarcik DC, 506

Nakazono T, 463
Nassar N, 14
Neau D, 161
Negredo E, 229
Neva F, 1
Newson R, 350
Nganga LW, 365
Nicholson JKA, 105
Nocita B, 44
Novotny G, 183
Núñez M, 426

Obel N, 124
Odhiambo JA, 365
Oliver-Vélez D, 405
Opravil M, 266
Ouellet LJ, 71

Pakker N, 116
Pallavicini F, 49
Pallavicini MG, 272
Paredes R, 229
Partisani M, 459
Paul JP, 176
Pereda I, 507
Pereira S, 350
Peri J-M, 336
Perno CF, 499
Perucci CA, 93
Petit JM, 245
Pezzotti P, 49
Phair JP, 168
Phanuphak P, 116
Phillips KA, 292
Piroth L, 245
Piscitelli SC, 210
Pollack L, 176
Pomerantz RJ, 20
Porta D, 93
Portier H, 245
Porto AF, 1
Powell M, 213
Priester M, 459
Pugatch DL, 135
Pumarola T, 35

Qian D, 130
Quirino T, 316

Rabian C, 443
Raffi F, 372
Rakotoambinina B, 443
Rañó A, 35
Rapiti E, 93
Ratterree M, 222
Re MCC, 315
Reinert SE, 135
Rey D, 459
Rezza G, 499
Ribeiro RM, 331
Ricci E, 316
Rimland D, 105
Rinaldo C, 168
Rindskopf DM, 301
Riva C, 499
Rizzardini G, 499
Roberts DE, 331
Robertson JR, 277
Robles RR, 405
Romeu J, 229
Rosenkranz S, 153
Rousaud A, 336
Rouzioux C, 99
Ruiz L, 229
Rutella S, 321
Ruxrungtham K, 116

Sahai H, 405
Salamon R, 372
Salzberger B, 237
Saville R, 63
Scheer S, 467
Schmidgall D, 260
Schmitt M-P, 459
Schreij G, 344
Schwarcz S, 467
Seage G III, 86
Seage GR III, 472
Sears C, 193
Segal Y, 153
Senese D, 499
Shafer RW, 377
Shapiro MF, 463
Sheppard HW, 472
Shor-Posner G, 56
Shulman NS, 377
Simon F, 99
Simoons M, 318
Skiest D, 14
Skolnik HS, 292
Smith JW, 14
Sonjai A, 116
Soriano V, 426
Spanish Lipodystrophy Group, 229
Spinosa S, 315
Stancliff S, 96
Steigbigel RT, 506
Stein M, 389
Stein MD, 463
Stephens B, 467
Strauss SM, 301
Supawitkul S, 415
Suwanagool S, 116
Svilar G, 381
Swiss HIV Cohort Study, 266

Tadolini M, 315
Taha TE, 202
Tamalet C, 99
Tan RCH, 222
Tarwater PM, 168
Thomsen HF, 124
Thorpe LE, 71
Tiengrim S, 116
Tiirikainen MI, 272
Torres A, 35
Trapido E, 56
Turner BJ, 20, 463
Turner D, 14

Ubel PA, 281
Ubolyam S, 116
Ungsedhapand C, 116

van der Ende ME, 318
van der Geest S, 344
Van Dooren S, 499
van Heeswijk RPG, 344
Vandamme A-M, 499
VanEtten-Lee ML, 86
Veglia F, 44
Veldkamp AI, 344
Vella S, 321
Vernazza PL, 209, 266
Verucchi G, 315
Viard J-P, 443
Vielhauer V, 237
Violin M, 499
Vitone F, 315
Vittinghoff E, 308

Wang J, 30
Watts H, 432
Weber R, 266
Weisman Z, 389
Weltzien EK, 193
Wille L, 237
Wilson TE, 289
Winters MA, 377
Woody GE, 86

Xu F, 415

Yap PL, 277
Yarber WL, 176
Yimsuan N, 116

Zeh C, 63
Zhang D, 20
Zolopa AR, 377

JAIDS Journal of Acquired Immune Deficiency Syndromes
27:512–518 © 2001 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes
Volume 27, 2001

Subject Index

Acquired immunodeficiency syndrome, pulmonary infiltrates in with HAART, 35
Adefovir, genotypic resistance to after adefovir dipivoxil therapy, 450
Adenovirus, in dendritic cells transduced with HIV-Nef, 417
Adherence, in early immunologic and virologic response to protease inhibitors, 372
Adolescents, HIV testing in substance abuse treatment setting, 135
Africa
  HIV-1 incidence among male workers in, 202
  HIV/AIDS vaccine study in, 381
  respiratory tract infections in HIV-1-infected adults in, 365
AIDS Clinical Trials Group 401, ritonavir/saquinavir effects on methadone in, 153
AIDS deaths, undiagnosed and unreported, 467
AIDS progression, temporal changes of with HAART (letter), 93
AIDS surveillance, San Francisco Medical Examiner report in, 467
AIDS vaccine trials, predicting participants in, 281
AJ276519/AJ276552 variations, in zidovudine genotypic resistance in HIV-1-infected newborns, 99
Animal disease model, of pathogenic determinants of CXCR4-specific $SHIV_{SF33A2}$ map to *env* region, 222
Anticardiolipin antibodies, highly active antiretroviral therapy effects and (letter), 507
Antiphospholipid antibodies, highly active antiretroviral therapy effects and (letter), 507
Antiretroviral therapy. *See also* Highly active antiretroviral therapy (HAART)
  beliefs about HIV transmission and condom use among women on, 289
  combination, low prevalence of cardiac abnormalities with (letter), 318
  comparative trials of in naive HIV-1-infected Thai patients, 116
  comparison of new drug resistance in, 331
  continued drug abuse during, 251
  genotypic resistance to drugs of in Italian patients (letter), 315
  in heavily pretreated HIV-1-infected patients, 124
  hepatic injury risk factors with, 426
  increased CD4 T-cell counts after initiation of, 168
  insulin resistance with in HIV-hepatitis C coinfection, 245
  lipodystrophic syndromes and hyperlipidemia with, 443
  lipodystrophy development and, 237
  long-term impact of on health care costs, 14
  long-term T-cell subset changes with, 266
  with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy, 229
  patient characteristics and in HIV-infected women, 20
  prognostic factors of combined viral load and $CD4^+$ cell count responses under, 161
  pulmonary infiltrates with, 35
  virologic, immunologic, and clinical responses to different regimens of, 350
Antitissue transglutaminase antibodies, in HIV infection (letter), 507
Apoptosis, in primary human umbilical vein endothelial cell cultures, 213
Asymptomatic HIV, long-term changes of with combination antiretroviral therapy for, 266
At-risk population, condom use among, 176

B-cell function, with indinavir-based therapy, 130
Bacterial infections, incidence and determinants of in HIV-positive patients receiving primary prophylaxis, 49
Baltimore, needle exchange program attendance in, 398
Behavioral predictors, of early immunologic and virologic response to protease inhibitors, 372
Biologic predictors, of early immunologic and virologic response to protease inhibitors, 372
Bisexual males, cofactors for HIV disease progression in, 308
Blood donors, cytokine profile and imunomodulation in human T-lymphotropic virus type 1-infected, 1
Bronchitis, in HIV-1-infected adults in Nairobi, 365

Candidiasis, CD4 cell counts and HIV RNA levels in, 44
Cardiac abnormalities, in HIV-seropositive population on antiretroviral combination therapy (letter), 318
CCR5-Δ32 genotypes, homozygous and heterozygous, in HIV resistance, 472
CCR5 expression, on memory and naive T cells in HIV-1 infection, 105
CD4 T-cell count
  with continued drug abuse during antiretroviral therapy, 251
  HIV RNA levels and in opportunistic infections, 44
  increase and plateau of after potent antiretroviral therapy initiation, 168
  in lipodystrophy in HIV-infected children, 30

long-term changes in with combination antiretroviral therapy, 266
with protease inhibitor- and nevirapine-containing regimens, 350
under triple antiretroviral therapy, 161
CD8 T-cell count, long-term changes in with combination antiretroviral therapy, 266
CD4 T cells, immune activation and decline in, 389
$CD8^+$ T cells, in human T-lymphotropic virus type 1, 1
Cell cultures, apoptotic effects of HIV-1 gp120 in, 213
Cell membrane-associated HIV-1 gp120, apoptotic effects of, 213
Cellular immunity, in human T-lymphotropic virus type 1, 1
Cervical abnormalities, evolution of with HIV-1 infection, 432
Cervical cancer
with HIV-1 infection, 432
HIV screening with diagnosis of (letter), 95
screening for in HIV-infected women, 463
Chemokine receptors, apoptotic effects of HIV-1 gp120 at, 213
Chicago, risk behaviors in young urban and suburban injection drug users in, 71
Cholesterol, in lipodystrophy development with stavudine versus zidovudine, 237
Clinical predictors, of early immunologic and virologic response to protease inhibitors, 372
Clinical response, to different initial protease inhibitor-containing and nevirapine-containing regimens, 350
Clinical trials
of anti-*Pneumocystis carinii/Toxoplasma gondii* primary prophylaxis, 49
in antiretroviral-naive HIV-1-infected Thai patients, 116
$Cmin/IC_{50}$ ratio, protease inhibitor pharmacokinetics and (letter), 210
Cofactor measurement, for HIV disease progression in homosexual and bisexual male cohort, 308
Commercial sex workers, among northern Thai women (letter), 414, 415
Community interventions, for young gay men, cost-effectiveness of, 482
Comparative genomic hybridization, in diffuse large-cell lymphoma, 272
Comparative trials, in antiretroviral-naive HIV-1-infected Thai patients, 116
Condom use
beliefs about HIV transmission and among women on antiretroviral therapy, 289
national trends in among at-risk heterosexuals in U.S., 176
Copper, plasma levels of in HIV-1-infected homosexual men, 56
Copper:zinc ratio, in plasma of HIV-1-infected homosexual men, 56
Cost-benefits, of long-term HAART, 14
Cost-effectiveness, of Mpowerment Project, 482
Cotrimoxazole, bacterial infections in HIV-positive patients receiving, 49
Cross-resistance, to stavudine after zidovudine monotherapy, 377
CXCR4 expression, on memory and naive T cells in HIV-1 infection, 105
CXCR4-specific $SHIV_{SF33A2}$, pathogenic determinants of, 222
Cyclosporin-A, in PBL P-glycoprotein efflux function defect, 321
Cytokines, in asymptomatic HTLV-I-infected blood donors, 1
Cytology, for cervical abnormalities with HIV-1 infection, 432
Cytomegalovirus infection, CD4 cell counts and HIV RNA levels in, 44

Dendritic cells, transduced with HIV *Nef*, 417
Didanosine
comparative trials of in antiretroviral-naive HIV-1-infected Thai patients, 116
pilot trial of in once-daily four-drug regimen, 260
Disclosure, of HIV status among HIV-positive men, 79
Disease progression
cofactors for in homosexual and bisexual male cohort, 308
temporal changes of with HAART (letter), 93
DNA copy number alterations, in HIV with diffuse large-cell lymphomas, 272
Dosing regimens, steady-state pharmacokinetics of with saquinavir plus ritonavir, 344
Drug abuse
detrimental effects of with HIV-1 treatment, 251
National Household Survey on, 86
Drug-drug interaction, of ritonavir/saquinavir and methadone, 153
Drug paraphernalia, risk behavior and, 71
Drug resistance
comparison of treatment regimens for, 331
to stavudine after zidovudine monotherapy, 377
to zidovudine in HIV-1-infected newborns, 99
Drug treatment setting, HIV testing in, 135
Drug users, concurrence of self-report and serotest result in, 301

Efavirenz
neuropsychiatric side effects of, 336
as substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load, 459
Endothelium, apoptotic effects of HIV-1 gp120 in, 213
env region, pathogenic determinants of CXCR4-specific $SHIV_{SF33A2}$ map to, 222
Epidemiologic methods, for CD4 T-cell counts after initiation of potent antiretroviral therapy, 168
Epstein-Barr virus, in diffuse large-cell lymphoma, 272
Ethics, in phase II AIDS vaccine trials, 281

Fat, regional changes of in HIV-infected children, 30
Fitness, of HIV-1 reverse transcriptase variants, 7
France
HIV incidence among women of childbearing age in, 492
zidovudine genotypic resistance in perinatal cohort of, 99

Gay men
cofactors for HIV disease progression in, 308
cost-effectiveness of interventions for, 482
Mpowerment Project for, 482
plasma zinc, copper, and copper:zinc ratios in, 56
self-disclosure of HIV status and sexual practices of, 79

substance use among, 86
Genotypic resistance
to adefovir and tenofovir after adefovir dipivoxil therapy, 450
to antiretroviral drugs in therapy-naive HIV-1-infected Italian patients (letter), 315
homozygous and heterozygous CCR5-Δ32 genotypes in, 472
to zidovudine in HIV-1-infected newborns, 99
Genotyping
for new drug resistance to antiretroviral regimens, 331
of virologic response to stavudine after zidovudine monotherapy, 377
gp120, apoptotic effects of, 213

HAART. *See* Highly active antiretroviral therapy (HAART)
Harlem
injection drug user frequency in, 405
Health care costs
long-term impact of HAART on, 14
Health promotion
HIV testing in, 292
Hepatic injury
risk factors for after HAART, 426
Hepatitis C
in young urban and suburban injection drug users, 71
Hepatitis C virus
in hepatic injury with HAART, 426
insulin resistance and in HIV-hepatitis C coinfection, 245
Hepatotoxicity
risk factors for with HAART (letter), 316
Heterosexual behavior
condom use trends and, 176
Heterosexual HIV transmission
mismatched human leukocyte antigen alleles protecting against, 277
Highly active antiretroviral therapy
antitissue transglutaminase antibodies and (letter), 507
CCR5 and CXCR4 expression in response to, 105
clinical, biologic, and behavioral predictors of early immunologic and virologic response to, 372
efavirenz as substitute for protease inhibitors in, 459
hepatic injury risk factors with, 426
hepatotoxicity risk factors in (letter), 316
HIV-protease inhibitors in P-glycoprotein efflux function defect in PBLs with, 321
HIV transmission after suspension of (letter), 209
immune activation and decline in CD4 T cells with, 389
lipodystrophic syndromes and hyperlipidemia with, 443
lipodystrophy development and, 237
long-term impact of on HIV-related health care costs, 14
protease inhibitor pharmacokinetics and Cmin/IC_{50} ratio in (letter), 210
Highly active antiretroviral therapy (HAART)
in heavily pretreated HIV-1-infected patients, 124
for HIV-infected women, provider and patient characteristics and, 20
hospitalization rates in urban cohort after, 143
pulmonary infiltrates with, 35
temporal changes of progression to AIDS with (letter), 93
HIV-1 gp120, apoptotic effects of, 213
HIV-1-infected homosexual men, plasma zinc, copper, copper:zinc ratio and survival in, 56
HIV-1-infected newborns, zidovudine genotypic resistance in, 99
HIV-1 infection
CCR5 and CXCR4 expression on memory and naive T cells in, 105
cervical abnormalities with, 432
drug abuse effects with treatment for, 251
incidence of among male workers at Sugar Estate in rural Malawi, 202
nevirapine with nelfinavir for, 124
respiratory tract infections with, 365
HIV-1 *pol* sequences, in heterosexual men and women, 499
HIV-1 recombinant forms, circulating, in heterosexual men and women, 499
HIV-1-related mortality, plasma zinc, copper, and copper:zinc ratios in, 56
HIV-1 reverse transcriptase, recombinant marker virus assay for fitness of variants, 7
HIV-1 RNA, with antiretroviral therapy, 116
HIV-1 subtypes, in heterosexual men and women, 499
HIV antibodies, assessing rapid lateral flow assay for detecting, 63
HIV-hepatitis C coinfection, insulin resistance and chronic hepatitis C infection with, 245
HIV-infected children, lipodystrophy in, 30
HIV-infected women, antiretroviral therapy regimen for, provider and patient characteristics in, 20
HIV infection
disease progression of, cofactors for in homosexual and bisexual male cohort, 308
incidence of among childbearing women in France, 492
in young urban and suburban injection drug users, 71
HIV-Nef, dendritic cells transduced with, 417
HIV plasma viral load, correlation with CD4 T-cell decline during HIV infection, 389
HIV-positive men, sexual practices among, 79
HIV-positive patients, bacterial infections in, 49
HIV-protease inhibitors, in PBL P-glycoprotein efflux function defect, 321
HIV quasispecies, new drug resistance in, 331
HIV resistance
comparison of treatment regimens for, 331
homozygous and heterozygous CCR5-Δ32 genotypes in, 472
HIV risk behavior, between-city variation in frequency of among Puerto Rican injection drug users, 405
HIV RNA
in opportunistic infections, 44
with protease inhibitor- and nevirapine-containing regimens, 350
with triple antiretroviral therapy, 161
HIV screening, in indigent women with newly diagnosed cervical cancer (letter), 95
HIV-seropositive population, low prevalence of cardiac abnormalities with antiretroviral combination therapy in (letter), 318
HIV status
self-reports and serotest results in drug users, 301
sexual practices and self-disclosure of, 79

HIV testing
deciding on setting for, 292
in substance abuse treatment setting, 135
HIV transmission
after HAART suspension (letter), 209
condom use and beliefs about, 289
HIV vaccine trials, willingness to participate in, 381
HLA-A Class I molecules, expressed in dendritic cells transduced with HIV-Nef, 417
HLA-B Class I molecules, expressed in dendritic cells transduced with HIV-Nef, 417
Homeless, syringe exchange programs for young injection drug users among, 193
Homosexual behavior, substance use and, 86
Homosexual men. *See* Gay men
Hospitalization rates, in urban cohort after HAART, 143
Human experimentation, in phase II AIDS vaccine trials, 281
Human leukocyte antigen alleles, mismatched, 277
Human papillomavirus, with HIV-1 infection in women, 432
Human T-lymphotropic virus type 1, cytokine profile and immunomodulation in, 1
Human umbilical vein endothelial cell cultures, apoptotic effects caused by viron-associated and cell membrane-associated HIV-1 gp120 in, 213
Human volunteers, in phase II AIDS vaccine trials, 281
Hyperlipidemia, in HIV-1-infected patients on triple therapy with protease inhibitors, 443

Immune activation
CCR5 and CXCR4 expression in, 105
correlation with CD4 T-cell decline during HIV infection, 389
Immune response
clinical, biologic, and behavioral predictors of, 372
to different initial protease inhibitor-containing and nevirapine-containing regimens, 350
in human T-lymphotropic virus type 1, 1
Immunochromatography test, assessment of in detection of HIV antibodies, 63
Immunologic tests, deciding on setting for, 292
Immunomodulation, in asymptomatic HTLV-I-infected blood donors, 1
Indinavir
effect of initiation on insulin sensitivity and B-cell function in HIV-infected patients, 130
pilot trial of in once-daily four-drug regimen, 260
Informed consent
for HIV/AIDS vaccine study in Ugandan military, 381
for phase II AIDS vaccine trials, 281
Injection drug users
among northern Thai women (letter), 414, 415
between-city variation in frequency of among Puerto Ricans, 405
hospitalization rates in after HAART, 143
needle exchange program attendance by, 398
pharmacy-based syringe access and practices of, 183
risk behaviors in, 71
syringe exchange program for in San Francisco, 193
Insulin resistance
chronic hepatitis C virus and in HIV-hepatitis C coinfected patients, 245
with indinavir-based therapy, 130
lipodystrophy and (letter), 506
Interferon-γ in human T-lymphotropic virus type 1, 1
Interleukin 2, in human T-lymphotropic virus type 1, 1
Interleukins, in human T-lymphotropic virus type 1, 1
Italian Cohort Naive for Antiretrovirals (ICONA), HIV-1 subtype prevalence in, 499
Italy
genotypic resistance to antiretroviral drugs in (letter), 315
prevalence of non-clade B HIV-1 strains in heterosexual men and women in, 499
temporal changes of progression to AIDS with HAART in (letter), 93

Jurkat transfection, of HIV-1 gp120 in human umbilical vein endothelial cell cultures, 213

Kaposi sarcoma, CD4 cell counts and HIV RNA levels in, 44
Kenya, respiratory tract infections in HIV-1-infected adults in, 365
Ki-67, CD4 T cell levels and, 389

Lamivudine
comparative trials of in antiretroviral-naive HIV-1-infected Thai patients, 116
pilot trial of in once-daily four-drug regimen, 260
Lateral flow assay, assessment of in detection of HIV antibodies, 63
Latino/Latina populations, between-city variation in frequency of injection drug use among, 405
Legislation, on pharmacy-based syringe access for injection drug users, 183
Letters to editor
Antitissue transglutaminase antibodies in HIV infection and effect of highly active antiretroviral therapy, 507
HIV transmission after suspension of highly active antiretroviral therapy, 209
Lipodystrophy and insulin resistance in patients with HIV, 506
Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy, 318
Oral mucosal lesions and HIV viral load in the Women's Interagency HIV Study (WIHS), 96
Peptides derived from salivary thrombospondin-1 replicate its anti-HIV effect: potential role in microbicide development, 91
Pharmacokinetic parameters of protease inhibitors and the Cmin/IC_{50} ratio: call for consensus, 210
Presence of genotypic resistance to antiretroviral drugs in a cohort of therapy-naive HIV-1-infected Italian patients, 315
Response to "Risk factors for HIV among northern Thai women: testing hypotheses or repeating assumptions?", 415
Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy, 316
Risk factors for HIV among northern Thai women: testing hypotheses or repeating assumptions?, 414

Screening for HIV infection in indigent women with newly diagnosed cervical cancer, 95
Temporal changes in progression to AIDS in the era of highly active antiretroviral therapy: Lazio Region, Italy, 1988 to June 2000, 93
Lipodystrophy
in HIV-1-infected patients on triple therapy with protease inhibitors, 443
with HIV-hepatitis C coinfection, 245
in HIV-infected children with high viral load and low $CD4^+$ cell count, 30
insulin resistance and in HIV infection (letter), 506
nevirapine therapy with, 229
with stavudine versus zidovudine, 237
Liver toxicity, with HAART, 426
Long-term outcomes, of HAART, 14
Longitudinal studies, of CD4 T-cell counts after initiation of potent antiretroviral therapy, 168
Lung disease, with HAART, 35
Lymphocytes, HIV-protease inhibitors in P-glycoprotein efflux function defect in, 321
Lymphoma, diffuse large-cell, DNA copy number alterations in, 272

Major histocompatibility complex, heterosexual HIV transmission and, 277
Malawi, HIV-1 incidence among male workers in, 202
Mathematical models, of new drug resistance in antiretroviral regimens, 331
Medical examiner, AIDS deaths reported by, 467
Memory T cells, CCR5 and CXCR4 expression on, 105
Methadone, ritonavir/saquinavir effect on stereoselective pharmacokinetics of, 153
Microbicide development, peptides from salivary thrombospondin-1 (letter), 91
Military, HIV/AIDS vaccine study in, 381
Minnesota, pharmacy-based syringe access and injection drug user practices in, 183
Mpowerment Project, cost-effectiveness of, 482
Mycobacterium avium complex disease, CD4 cell counts and HIV RNA levels in, 44

Narcotic effect, ritonavir/saquinavir and, 153
Needle exchange programs
for homeless young injection drug users in San Francisco, 193
sociobehavior and needle acquisition patterns correlation with attendance in, 398
Nelfinavir, nevirapine with in heavily pretreated HIV-1-infected patients, 124
Neuropsychiatric side effects, of efavirenz, 336
Nevirapine
with nelfinavir in heavily pretreated HIV-1-infected patients, 124
in protease inhibitor-experienced patients with HIV-associated lipodystrophy, 229
virologic, immunologic, and clinical responses to, 350
New York City, injection drug user frequency in, 405
Newborns, zidovudine genotypic resistance in, 99
Non-Hodgkin's lymphoma, DNA copy number alterations in, 272
Nonnucleoside reverse transcriptase inhibitors
neuropsychiatric side effects of, 336
in PBL P-glycoprotein efflux function defect, 321
Nucleoside analogs, lipodystrophic syndromes and hyperlipidemia with, 443
Nucleoside reverse transcriptase inhibitors, in heavily pretreated HIV-1-infected patients, 124

Occupational cohort, HIV-1 incidence among, 202
Once-daily four-drug regimen, indinavir, ritonavir, didanosine, and lamivudine in, 260
Opportunistic infections, CD4 cell counts and HIV RNA levels in, 44
Oral mucosal lesions, HIV viral load and in women (letter), 96
Outcomes, long-term impact of HAART on, 14

P-glycoprotein, efflux function defect of and HIV-protease inhibitors, 321
Papanicolaou smear
for cervical abnormalities with HIV-1 infection, 432
in cervical cancer screening in HIV-infected women, 463
Pathogenesis, determinants of in mucosally transmissible CXCR4-specific SHIV, 222
Patient
characteristics of in HIV-infected women's antiretroviral therapy regimen, 20
nonadherence of with continued drug abuse, 251
recruitment of for phase II AIDS vaccine trials, 281
Pediatric AIDS, lipodystrophy in, 30
Peptides, from salivary thrombospondin-1 (letter), 91
Peripheral blood lymphocytes, HIV-protease inhibitors in P-glycoprotein efflux function defect in, 321
Pharmacokinetics
of indinavir, ritonavir, didanosine, and lamivudine, 260
of methadone, ritonavir/saquinavir effects on, 153
of protease inhibitors (letter), 210
of twice-daily dosing of saquinavir plus ritonavir, 344
Pharmacy-based syringe access, injection drug use practices and, 183
Phenotypic analysis, of study GS-96-408, 450
Physicians practice patterns, in HIV-infected women's antiretroviral therapy regimen, 20
Pilot study, of indinavir, ritonavir, didanosine, and lamivudine in once-daily four-drug regimen, 260
Plasma HIV RNA, undetectable levels of, efavirenz treatment with, 459
Pneumocystis carinii pneumonia
bacterial infections and primary prophylaxis for, 49
CD4 cell counts and HIV RNA levels in, 44
Pneumonia
with HAART, 35
in HIV-1-infected adults in Nairobi, 365
pol gene, in heterosexual men and women, 499
Polymerase chain reaction, for fitness of HIV-1 reverse transcriptase variants, 7
Potent antiretroviral therapy, increase and plateau of CD4 T-cell counts after initiation of, 168
Practice guidelines, for HIV-infected women, 20

Predictors, of early immunologic and virologic response to protease inhibitors, 372
Pregnancy, HIV incidence during, 492
PREVAGEST surveys, of women of childbearing age in France, 492
Prevention
  among young gay men, cost-effectiveness of, 482
  deciding on health service setting for, 292
  for homeless injection drug users, 193
  mismatched human leukocyte antigen alleles in, 277
Prevention trends
  condom use among at-risk heterosexuals and, 176
Prognostic factors, of combined viral load and $CD4^+$ cell count responses under triple antiretroviral therapy, 161
Prophylaxis, anti-*Pneumocystis carinii/Toxoplasma gondii*, 49
Prospective studies, of neuropsychiatric side effects of efavirenz, 336
Prostitution, among northern Thai women (letter), 414, 415
Protease inhibitors
  clinical, biologic, and behavioral predictors of early immunologic and virologic response to, 372
  insulin sensitivity and B-cell function with, 130
  lipodystrophic syndromes and hyperlipidemia with, 443
  in lipodystrophy in HIV-infected children, 30
  long-term impact of on HIV-related health care costs, 14
  nevirapine-based triple therapy in patients using, 229
  in PBL P-glycoprotein efflux function defect, 321
  pharmacokinetic parameters of (letter), 210
  steady-state pharmacokinetics of twice-daily dosing of, 344
  substitute for in HIV-1-infected patients with undetectable plasma viral load, 459
  virologic, immunologic, and clinical responses to regimens containing, 350
Protease sequence analysis, for non-clade B HIV-1 strains in heterosexual men and women, 499
Psychiatric symptoms, with efavirenz therapy, 336
Puerto Rico, injection drug user frequency in, 405
Pulmonary infiltrates, in HIV-infected patients in era of HAART in Spain, 35

Quality-adjusted life years, with community-level intervention for young gay men, 482
Quality of health care, provider and patient characteristics in, 20
Quality of life, with neuropsychiatric side effects of efavirenz, 336

Rapid assay, assessment of in detection of HIV antibodies, 63
Recombinant marker virus assay, for relative fitness of HIV-1 reverse transcriptase variants, 7
Research design, in phase II AIDS vaccine trials, 281
Resistance, to adefovir and tenofovir, 450
Respiratory tract infection, in HIV-1-infected adults in Nairobi, 365
Reverse transcriptase, genotypic change in with adefovir dipivoxil therapy, 450
Reverse transcriptase analysis, for non-clade B HIV-1 strains in heterosexual men and women, 499
Reverse transcriptase inhibitors
  comparative trials of in anti-retroviral-naive HIV-1-infected patients, 116
  in HAART, 459
  neuropsychiatric side effects of, 336
  in PBL P-glycoprotein efflux function defect, 321
Risk behaviors
  among homeless injection drug users, 193
  between-city variation in frequency of among Puerto Rican injection drug users, 405
  condom use trends and, 176
  HIV testing and, 135
  pharmacy-based syringe access and among injection drug users, 183
  in young urban and suburban injection drug users, 71
Risk factors
  among northern Thai women (letter), 414, 415
  for lipodystrophy in HIV-infected children, 30
Ritonavir
  pilot trial of in once-daily four-drug regimen, 260
  plus saquinavir, steady-state pharmacokinetics of, 344
Ritonavir/saquinavir, in stereoselective pharmacokinetics of methadone, 153

Safe sex, in HIV-positive men, 79
Salivary thrombospondin-1, anti-HIV effect of peptides from (letter), 91
San Francisco, syringe exchange programs for homeless young injection drug users in, 193
San Francisco Medical Examiner, AIDS deaths reported by, 467
Saquinavir
  plus ritonavir, steady-state pharmacokinetics of, 344
  in stereoselective pharmacokinetics of methadone, 153
Screening, for cervical cancer in HIV-infected women, 463
Self-disclosure, of HIV status, sexual practices in HIV-positive men and, 79
Self-report, of drug users' HIV status, 301
Self-testing, for HIV, 292
Serodiagnosis, deciding on setting for, 292
Serologic testing
  of drug users' HIV status, 301
  rapid lateral flow assay in, 63
Seroprevalence
  survey of among women of childbearing age in France, 492
  in young urban and suburban injection drug users, 71
Serostatus, of drug users, 301
Sexual behavior
  beliefs about HIV transmission and, 289
  condom use trends and, 176
  in HIV-positive men, 79
  of young gay men with community-based intervention, 482
Sexual transmission, mismatched human leukocyte antigen alleles protecting against, 277
Sociobehavior, needle exchange program attendance and, 398
Southeast Asia, comparative trials of anti-retroviral-naive HIV-1-infected patients in, 116
Spain, pulmonary infiltrates in HIV-infected patients on HAART, 35

Stavudine
genotypic correlates of virologic response to, 377
lipodystrophy development and, 237
in lipodystrophy in HIV-infected children, 30
Stereoselective pharmacokinetics, of methadone, ritonavir/saquinavir effects on, 153
Sub-Saharan Africa, HIV-1 incidence among male workers in, 202
Substance abuse
among gay men, 86
antiretroviral therapy regimen and for HIV-infected women, 20
HIV testing and treatment for, 135
Surveillance cytology, for cervical abnormalities with HIV-1 infection, 432
Survival rates, plasma zinc, copper, and copper:zinc ratios in, 56
Syringe exchange programs
for homeless young injection drug users in San Francisco, 193
injection drug use practices and, 183
needle acquisition patterns and sociobehavioral correlated with, 398
Syringe sharing
among homeless injection drug users, 193
in young urban and suburban injection drug users, 71

T-cell subsets, long-term changes of with combination antiretroviral therapy, 266
T cells, CCR5 and CXCR4 expression on, 105
Tenofovir, genotypic resistance to after adefovir dipivoxil therapy, 450
Thailand
comparative trials of anti-retroviral-naive HIV-1-infected patients in, 116
risk factors for HIV among women in (letter), 414, 415
Therapeutic regimens
comparison of for new drug resistance, 331
of indinavir, ritonavir, didanosine, and lamivudine, 260
virologic, immunologic, and clinical responses to, 350
Therapeutic response, to triple antiretroviral therapy, 161
Thrombospondin-1, anti-HIV effect of peptides from (letter), 91
Toxoplasma gondii, bacterial infections and primary prophylaxis for, 49
Transfection, of HIV-1 gp120, 213
Transmission, after HAART suspension (letter), 209
Treatment efficacy, drug resistance and, 331
Treatment failure, with protease inhibitor- and nevirapine-containing regimens, 350
Treatment simplification, in protease inhibitor-experienced patients with HIV-associated lipodystrophy, 229
Triple antiretroviral therapy
lipodystrophic syndromes and hyperlipidemia with, 443
nevirapine-based, in protease inhibitor-experienced patients, 229
prognostic factors of combined viral load and $CD4^+$ cell count responses under, 161
Triple nucleoside reverse transcriptase inhibitor therapy, comparative trials of in anti-retroviral-naive HIV-1-infected patients, 116
Tumor clonality, in diffuse large-cell lymphoma, 272

Uganda, HIV/AIDS vaccine study in, 381
Umbilical vein endothelial cells, apoptotic effects caused by viron-associated and cell membrane-associated HIV-1 gp120 in, 213
Undiagnosed AIDS, medical examiner data on, 467
United States, condom use among at-risk heterosexuals in, 176
Urban cohort, hospitalization rates in after HAART, 143

Vaccine trials
predicting participants in, 281
willingness to participate in, 381
Verapamil, in PBL P-glycoprotein efflux function defect, 321
Viral fitness, of HIV-1 reverse transcriptase variants, 7
Viral load
with continued drug abuse during antiretroviral therapy, 251
correlation with CD4 T-cell decline during HIV infection, 389
in lipodystrophy in HIV-infected children, 30
oral mucosal lesions and in women with HIV (letter), 96
with protease inhibitor- and nevirapine-containing regimens, 350
under triple antiretroviral therapy, 161
undetectable, efavirenz treatment with, 459
Viral pathogenesis, of CXCR4-specific $SHIV_{SF33A2}$ map to *env* region, 222
Viremia, CD4 T cell levels and immune activation in, 389
Viroimmunologic response, to triple antiretroviral therapy, 161
Virologic response
clinical, biologic, and behavioral predictors of, 372
to different initial protease inhibitor-containing and nevirapine-containing regimens, 350
Viron-associated HIV-1 gp120, apoptotic effects of, 213
Virus particles, in human umbilical vein endothelial cell cultures, 213

Women
antiretroviral therapy regimen for, provider and patient characteristics in, 20
beliefs about HIV transmission and condom use among, 289
cervical abnormalities with HIV-1 infection in, 432
cervical cancer screening in HIV-infected, 463
HIV incidence estimates in childbearing years, 492
HIV screening for with newly diagnosed cervical cancer (letter), 95
hospitalization rates in after HAART, 143
oral mucosal lesions with HIV viral load in (letter), 96
risk factors for HIV among (letter), 414, 415

Zidovudine
comparative trials of in antiretroviral-naive HIV-1-infected Thai patients, 116
genotypic correlates of virologic response to stavudine after monotherapy with, 377
genotypic resistance to in HIV-1-infected newborns, 99
lipodystrophy development and, 237
Zinc, plasma levels of in HIV-1-infected homosexual men, 56